Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.
1 . A pharmaceutical composition formulated for oral administration comprising a pharmaceutically acceptable excipient and a compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , and X 14 are each independently selected from the group consisting of hydrogen and deuterium,
and wherein
at least one of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , and X 14 is deuterium.
2 . The pharmaceutical composition of claim 1 , wherein any position in the compound of formula (I) selected as having deuterium independently has a minimum deuterium incorporation of at least 45%,
or a pharmaceutically acceptable salt thereof.
3 . The pharmaceutical composition of claim 1 comprising the pharmaceutically acceptable salt of the compound of formula (I).
4 . The pharmaceutical composition of claim 1 , wherein the composition is a tablet composition formulated for oral administration.
5 . The pharmaceutical composition of claim 1 , wherein the composition is an oral, modified-release pharmaceutical composition for oral administration to a subject, whereby, upon oral administration of the modified-release pharmaceutical composition to the subject, a steady release of said compound, or pharmaceutically acceptable salt thereof, from the modified-release pharmaceutical composition is maintained so that no neurologically toxic spike in the subject's plasma occurs during the release period of said compound, or pharmaceutically acceptable salt thereof, from said pharmaceutical composition.
6 . The pharmaceutical composition of claim 1 , wherein the composition is an oral, modified-release pharmaceutical composition for oral administration to a subject, said oral, modified-release pharmaceutical composition comprising:
(a) the compound of claim 1 , or a pharmaceutically acceptable salt thereof in an amount in the range of from about 0.01 to about 10 mg/kg body weight of the subject; and
(b) a pharmaceutically acceptable excipient;
whereby, upon oral administration of the oral, modified-release pharmaceutical composition to the subject, a steady release of said compound, or pharmaceutically acceptable salts thereof from the oral, modified-release pharmaceutical composition is maintained so that no neurologically toxic spike in the subject's plasma occurs during the release period of said compound or pharmaceutically acceptable salts thereof from said oral, modified-release pharmaceutical composition.
7 . The pharmaceutical composition of claim 1 formulated for modified release.
8 . The pharmaceutical composition of claim 1 , wherein the compound is
9 . The pharmaceutical composition of claim 4 , wherein the tablet composition is single-layer.
10 . The pharmaceutical composition of claim 4 , wherein the tablet composition is a modified-release tablet.
11 . The pharmaceutical composition of claim 4 , wherein the composition comprises a combination of (i) a water-insoluble neutrally charged non-ionic matrix; and (ii) a polymer carrying one or more negatively charged groups.
12 . A method of inhibiting N-methyl-d-aspartate (NMDA) receptor activity, said method comprising: contacting the NMDA receptor with an effective amount of the pharmaceutical composition of claim 1 , or a pharmaceutically acceptable salt thereof.
13 . A method of treating a disease or condition in a subject comprising the step of administering to said subject the pharmaceutical composition of claim 4 .
14 . A method of treating a disease or condition in a subject comprising the step of administering said subject an effective amount of the pharmaceutical composition of claim 1 .
15 . The method of claim 13 , wherein said disease or condition is levodopa-induced dyskinesia; dementia, tinnitus, depression, pain, agitation resulting from or associated with Alzheimer's disease, pseudobulbar effect, autism, Bulbar function, anxiety, Alzheimer's disease, schizophrenia, diabetic neuropathy, suicidality, post-traumatic stress disorder (PTSD).
16 . The method of claim 13 , wherein said disease or condition is a psychiatric or mental disorder.
17 . The method of claim 16 , wherein said disease or condition is schizophrenia, a mood disorder, substance induced psychosis, major depressive disorder (MDD), bipolar disorder, bipolar depression (BDep), post-traumatic stress disorder (PTSD), suicidal ideation, anxiety, obsessive compulsive disorder (OCD), or treatment-resistant depression (TRD).
18 . A method for treating a subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, for which ketamine treatment is indicated, wherein the subject is in need of the treatment, said method comprising:
administering to the subject the pharmaceutical composition of claim 1 , in an effective amount for treating, preventing and/or managing the disease, disorder, or condition.
19 . The method of claim 18 , wherein the disease, disorder, or condition is selected from a group consisting of pain, depression, anxiety, traumatic brain injury, stroke, migraines, epilepsy, schizophrenia, asthma, post traumatic disorder, bipolar disorder, alcohol dependence, Alzheimer disease, suicidality, autism, diabetic neuropathy, tinnitus, levodopa-induced dyskinesia, speudobulbar effect, Bulbar function and the like.